We examined the effects on allosteric modulation and ligand binding of the mutation of amino acid residues of the human A 3 adenosine receptor (A 3 AR) that are hypothesized to be near one of three loci: the putative sodium binding site, the putative ligand binding site, and the DRY motif in transmembrane helical domain 3. The effects of three heterocyclic allosteric modulators [the imidazoquinoline 2-cyclopentyl-4-phenylamino-1H-imidazo [4,5-c] 
I]iodobenzyl)-5Ј-N-methylcarboxamidoadenosine, were compared at wild-type (WT) and mutant A 3 ARs. The F182A 5.43 and N274A 7.45 mutations eliminated the allosteric effects of all three modulators but had little effect on agonist binding. The N30A
1.50 and D58N 2.50 mutations abolished the allosteric effects of DU124183 and VUF5455, but not HMA, whereas the D107N 3.49 mutation abolished the effects of DU124183, but not HMA or VUF5455. The T94A 3.36 , H95A 3.37 , K152A EL2 , W243A 6.48 , L244A 6.49 , and S247A
6.52 mutations did not influence allosteric effects of the modulators. Sodium ions (100 mM), which modulate agonist binding at a variety of receptors, caused an ϳ80% inhibition of agonist binding in WT A 3 ARs but did not show any effect on D58N 2.50 , D107N 3.49 , and F182A 5.43 mutant receptors. In contrast, NaCl induced a modest increase of agonist binding in N30A
1.50 and N274A 7.45 mutant receptors. NaCl decreased the dissociation rate of the antagonist radioligand [ The G protein-coupled receptors (GPCRs) are a principal target of currently used drugs. Traditionally, the development of such drugs has been concentrated on optimizing the interaction of molecules with the binding site for endogenous agonists and competitive antagonists (orthosteric site). In addition to the orthosteric site, drugs can interact with binding sites on the receptor molecule that are distinct from the orthosteric site (i.e., allosteric sites) (Bruns and Fergus, 1990) . Several lines of evidence suggest that allosteric modulators could offer advantages over orthosteric ligands (Christopoulos, 2002; Christopoulos and Kenakin, 2002) , such as greater selectivity.
In the field of ion channel-coupled GABA A receptors, benzodiazepines as positive allosteric modulators have been used successfully in therapeutics. By contrast, directly acting agonists for GABA A receptors have not found therapeutic application because of their potential side effects (Macdonald and Olsen, 1994) . The positive allosteric modulator for nicotinic receptors, galanthamine, has also been successfully used in the treatment of Alzheimer's disease (Olin and Schneider, 2002) . In the field of GPCRs, it is encouraging that, in terms of therapeutic application, positive allosteric modulators for the calcium-sensing GPCR are now in clinical trials for the treatment of primary hyperparathyroidism (Conigrave et al., 2000) .
Allosteric modulators of adenosine receptors (ARs) are of potential clinical use (Linden, 1997) . Allosteric modulation of the A 1 AR has been extensively investigated (Bruns and Fergus, 1990; Linden, 1997; Kourounakis et al., 2001) . Allosteric modulation of the A 2A AR has also been reported (Gao and IJzerman, 2000) . Allosteric modulators for the A 3 AR, including DU124183, VUF5455, and amiloride derivatives, have recently been identified and characterized ( Fig. 1) (Gao et al., , 2002b (Gao et al., , 2003 . However, the identity of amino acid residues in the A 3 AR that are involved in the allosteric modulation has not previously been studied.
To identify amino acid residues that may participate in the response to allosteric modulators, we examined the roles of selected residues from transmembrane helical domains (TMs) 1, 2, 3, 5, 6 and 7 and the second extracellular loop (EL) of the human A 3 AR by site-directed mutagenesis. The residues were selected based on proximity to the putative sodium binding site, the conserved DRY motif in TM3, or the putative ligand binding site ).
Materials and Methods
Materials. The QuikChange site-directed mutagenesis kit was purchased from Stratagene (La Jolla, CA). A monoclonal antibody (12CA5) against a hemagglutinin epitope and adenosine deaminase were obtained from Roche Molecular Biochemicals (Indianapolis, IN) and goat anti-mouse IgG antibody conjugated with horseradish peroxidase was from Sigma (St. Louis, MO). Oligonucleotides used were synthesized by Bioserve Biotechnologies (Laurel, MD). The vector pcDNA3 was purchased from Invitrogen (Carlsbad, CA). Human A 3 AR cDNA was provided by M. Atkinson, A. Townsend-Nicholson, and P. R. Schofield (Garvan Medical Institute, Sydney, Australia) and was subcloned in pcDNA3 as pcDNA3/hA 3 R. -(3-iodobenzyl)adenosine-5Ј-N-methyluronamide (Cl-IB-MECA) and 5-(N,N-hexamethylene)amiloride (HMA) were from Sigma (St. Louis, MO). DU124183 and VUF5455 were from Leiden/Amsterdam Center for Drug Research (Leiden, The Netherlands). All the enzymes used in this study were obtained from New England Biolabs (Beverly, MA).
Site-Directed Mutagenesis. The protocols used were as described in the QuikChange site-directed mutagenesis kit (La Jolla, CA). Mutations were confirmed by DNA sequencing.
Numbering Scheme of GPCRs. The standardized numbering system of van Rhee and Jacobson (1996) was used to identify residues in the transmembrane domains of various receptors. Each residue is identified by two numbers: the first corresponds to the TM in which it is located, and the second indicates its position relative to the most conserved residue in that helix, arbitrarily assigned to 50. For example, His3.37 is the histidine in TM3 located 13 residues before the most conserved arginine, R3.50; Asn7.45 corresponds to Asn274.
Transient Expression of Wild-Type and Mutant Receptors in COS-7 Cells. COS-7 (African green monkey kidney) cells were grown in 100-mm cell culture dishes containing Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100 g/ml streptomycin, and 2 mol/ml glutamine. Cells were washed with phosphate-buffered saline containing calcium and then transfected with plasmid DNA (10 g/dish) using the DEAE-dextran method (Cullen, 1987) for 1 h. The cells were then treated with 100 M chloroquine for 3 h in culture medium and cultured for an additional 48 h at 37°C and 5% CO 2 .
Membrane Preparation. After 48 h of transfection, COS-7 cells were harvested and homogenized using a Polytron homogenizer. The homogenates were centrifugated at 20,000g for 20 min, and the resulting pellet was re-suspended in 50 mM Tris-HCl buffer, pH 8.0, and stored at Ϫ80°C in aliquots. The protein concentration was determined by using the method of Bradford (1976) .
[ 125 I]I-AB-MECA Binding Assay. For competitive binding assay, each tube contained 100 l of membrane suspension, 50 l of [ 125 I]I-AB-MECA (final concentration, 0.5 nM), and 50 l of increasing concentrations of the test ligands in Tris-HCl buffer (50 mM, pH 8.0) containing 10 mM MgCl 2 and 1 mM EDTA. Nonspecific binding was determined using 10 M Cl-IB-MECA. The mixtures were incubated at 25°C for 60 min. For dissociation kinetics, the protocols used were as we described previously . Briefly, [ 125 I]I-AB-MECA (0.5 nM) was preincubated with WT and mutant receptor membranes (8-20 g protein) for 1 h at 25°C. Dissociation was started by adding 10 M Cl-IB-MECA in the absence or presence of an allosteric modulator. Binding reactions were terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandell, Gaithersburg, MD). Filters were washed three times with 9 ml of ice-cold buffer. Radioactivity was determined in a ␥-counter (5500B; Beckman Coulter, Fullerton, CA).
Binding of the Selective Antagonist, [ 3 H]PSB-11, to A 3 ARs. Membranes (60-100 g protein) were incubated with 8 nM [
3 H]PSB-11 (Mü ller et al., 2002) at 25°C in a total assay volume of 400 l for 60 min. Nonspecific binding was measured in the presence of 10 M Cl-IB-MECA. Binding reactions were terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandel, Gaithersburgh, MD).
Statistical Analysis. Binding parameters were estimated using Prism software (GraphPAD, San Diego, CA). IC 50 values obtained from competition curves were converted to K i values using the Cheng and Prusoff (1973) equation. Data were expressed as mean Ϯ S.E.
Computational Methods. All calculations were performed on an SGI Octane workstation (SGI, Mountain View, CA). All ligand structures were constructed using the "Sketch Molecule" of SYBYL 6.8 (Tripos Inc., St. Louis, MO). A conformational search of allosteric modulators was performed by grid search, rotating in 60°, 180°, and Ϫ60°for all flexible bonds and 0 or 180°for the amide bond with Merck Molecular force field (MMFF94) and charge. After clustering the low-energy conformers from the result of the conformational search, the representative ones from all groups were reoptimized by semiempirical molecular orbital calculations using the PM3 method in the MOPAC 6.0 package. Each of the lowest energy conformation from PM3 optimization was used for DISCO (DIStance COmparisons) computation (Martin et al., 1993) , followed by default option.
A human A 3 receptor model was built using a homology modeling from the recently published X-ray structure of bovine rhodopsin (Palczewski et al., 2000) as we described previously (Gao et al., 2002a,c) . The Amber all-atom force field with fixed dielectric constants as 4.0 was used for all calculations, terminating when the conjugate gradient was 0.05 kcal/mol/Å. For the conformational refinement of A 3 AR, the optimized structures were then used as the starting point for subsequent 50-ps molecular dynamics (MD), during which the protein backbone atoms in the secondary structures were constrained as in the previous step. The options of MD at 300 K with 0.2-ps coupling constant were a time step of 1 fs and a nonbonded update every 25 fs. The lengths of bonds with hydrogen atoms were constrained according to the SHAKE algorithm (Ryckaert et al., 1977) . The average structure from the last 10-ps trajectory of MD was reminimized with backbone constraints in the secondary structure and then without any constraints as described above.
Flexible docking was facilitated through the "FlexiDock" utility (Judson, 1997) in the Biopolymer module of SYBYL 6.8 (Tripos, St. Louis, MO). During flexible docking, the flexible bonds of allosteric modulators and the side chains of the putative binding site in the A 3 AR were defined with rotatable bonds. After adding hydrogens to the receptor, atomic charges were recalculated using Kollman Allatom for the protein and Gasteiger-Hü ckel for the ligand. Default FlexiDock parameters were set at 3000-generation for genetic algorithms. To increase the binding interaction, the torsion angles of the side chains that directly interacted within 5 Å of the ligands according to the results of FlexiDock were manually adjusted. Finally, the complex structure was minimized using an Amber force field with fixed dielectric constant (4.0), until the conjugate gradient reached 0.1 kcal/mol/Å.
Results
Agonist and Antagonist Binding to WT and Mutant A 3 ARs. Before studying the possible involvement of residues in the allosteric modulation, we first examined the agonist and antagonist binding properties of WT and mutant A 3 ARs using an agonist radioligand, [
125 I]I-AB-MECA, and an antagonist radioligand, [ 3 H]PSB-11. Several of the A 3 AR mutations examined here (Table 1) were also studied previously (Gao et al., 2002a) , whereas others were constructed based on predictions of molecular modeling and by homology to other GPCRs. mM NaCl induced an approximately 50% inhibition of the agonist binding (Fig. 4) . The effect of sodium ions in the S247A 6.52 mutant receptor was essentially the same as that in WT (Fig. 4) (Gao et al., , 2002b (Gao et al., , 2003 7.45 mutations induced only a slight reduction in the affinity of these allosteric modulators for ligand-unoccupied receptors. The K152A mutations did not influence the affinity of HMA but induced a 3-and 8-fold decrease of affinity of DU124183 and VUF5455, respectively. Interestingly, the W243A 6.48 mutation induced a 4-fold increase of the affinity of HMA (Fig. 5) , but resulted in a 3-and 10-fold decrease of the affinity for DU124183 and VUF5455, respectively. Hence, the W243A 6.48 mutation selectively enhanced the affinity of the amiloride analog, HMA. To further confirm the unique binding properties of amiloride analogs at this mutant receptor, we further tested the effect of amiloride on WT and W243A 6.48 mutant receptors. The IC 50 values of amiloride were 74 Ϯ 12 and 36 Ϯ 8 M for WT and W243A 6.48 mutant receptors, respectively, consistent with the gain in affinity observed with the amiloride analog, HMA. (Gao et al., 2002a,c) . It should be noted that the loss of ligand binding may also be caused by the incorrect folding of the receptor, because the expression of these receptors on the cell surface was not determined. Mutation of L244 6.49 or S247 6.52 was without the effect on agonist/antagonist affinity, and these residues did not participate in direct interaction with the ligand according to the model, notwithstanding their proximity to the orthosteric site.
The docking of allosteric modulators to the A 3 AR was necessarily more complex, because multiple binding modes had to be considered. The effects of various Ala mutations on A 3 AR binding affinity were generally less pronounced for the allosteric modulators than for the pure orthosteric ligands. The allosteric modulators DU124183 and VUF5455 generally showed similar effects in the inhibition of agonist binding at Ala mutant receptors, with the exception of F182A 5.43 , of which mutation to Ala decreased selectively the affinity of DU124183. However, in the case of HMA, most of the mutant receptors except N30A
1.50 and H95A 3.37 displayed no significant effect on the binding affinity. In relation to DU124183 as a reference molecule, VUF5455 had more common overlap volume (130.6 Å 3 ) than did HMA (88.3 Å 3 ), as indicated by a similarity analysis using the DISCO software module, which identified matches among all active compounds based on the intermolecular distances between features. Thus, the binding sites of DU124183 and VUF5455 on the A 3 AR may be more similar to each other compared with that of HMA. Therefore, we selected VUF5455 as the first allosteric modulator to be docked to the receptor at multiple potential binding sites. In the study of docking of VUF5455 to the unliganded A 3 AR using the automatic docking program FlexiDock, the binding at the orthosteric site was energetically more favorable than the binding either at the presumed sodium binding site, near D58 2.50 , or at the top of the TM7 region. However, in docking VUF5455 to the A 3 AR/Cl-IB-MECA complex at either TM2 or TM7, the latter potential binding site at the top of the TM7 region, which was in contact with extracellular loops, was energetically more favorable (Fig. 6) .
In the A 3 AR model constructed from the X-ray structure of rhodopsin, several intramolecular TM networks stabilized the inactive conformation of the A 3 AR through hydrophilic interactions as well as hydrophobic contacts. Similar H-bonding networks were found in rhodopsin and were also proposed to exist in the A 2A AR (data not shown). In the A 3 AR, a group of hydrophilic amino acids (N274 7.45 , S275 7.46 , N278 7.49 ) surrounding and including D58 2.50 formed a Hbonding network (Fig. 7A) . In addition, H-bonds to S97 3.39 and W243
6.48 also stabilized N274 7.45 . Another hydrophilic residue, N30
1.50 , which was near D58 2.50 , formed a H-bond to the backbone of S275 7.46 . Another H-bonding network evident in the A 3 AR model involved the DRY motif at the cytosolic end of TM3 (Fig. 7B) . Table 3.   TABLE 3 Dissociation rates of the antagonist radioligand ͓ 3 H͔PSB-11 from WT and mutant receptors in the absence and presence of allosteric modulators Results were expressed as means Ϯ S.E. from three independent experiments. The dissociation rates (k Ϫ1 ) were determined at 25°C. The final concentration of ͓ 3 H͔PSB-11 used in this experiment was 8 nM. 
Discussion
We examined the effects on allosteric modulation and ligand binding of the mutation of amino acid residues of the human A 3 AR that are hypothesized to be near one of three loci: the putative sodium binding site, the putative ligand binding site, and the DRY motif in TM3. Because it has been established that these three heterocyclic A 3 AR allosteric modulators (DU124183, VUF5455, and HMA) also compete for radioligand binding at the orthosteric binding site, their affinities at WT and mutant receptors were examined. As for other heterocyclic antagonists (Gao et al., 2002a) , the most substantial loss of affinity was observed for the H95A mutation (10-to 30-fold). Also, VUF5455 was selectively reduced in affinity at the N30A, D107N, K152A, and W243A mutant receptors. Conversely, DU124183 was selectively reduced in affinity at the F182A mutant receptor. Thus, the structurally diverse allosteric modulators have specific residues associated with the binding of each.
It was shown that certain residues contributed differently to ligand binding and to allosteric modulation either by heterocyclic derivatives or by sodium ions, suggesting a possible separation of the structural requirements for all of these processes. Most notably, the Ala substitution of Phe182 5.43 or Asn274 7.45 abolished the ability of all of the allosteric modulators, including HMA, DU124183, and VUF5455, to influence the agonist dissociation rate. Thus, although not critical for agonist binding, Phe182 5.43 and Asn274 7.45 were required in allosteric modulation.
Also, specific regions of the receptor were involved in ligand binding but seemed not to influence allosteric effects. For example, W243A
6.48 mutation caused a 4-fold increase of the affinity HMA for the unoccupied receptors, but it did not influence the effect of HMA on the dissociation of the agonist [ 125 I]I-AB-MECA. Concerning the mutations that evidently did not affect the allosterism, it must be noted that the effects of the allosteric ligands on the mutant receptors were studied at single concentrations of the compounds. Therefore, the present study can not rule out the possibility that a null mutation may in some instances be a counterbalancing effect on both parameters.
It was demonstrated that DU124183 (10 M) inhibits [ 125 I]I-AB-MECA binding at WT by ϳ 80% but only 10% at H95A mutant (Fig. 5B ), yet the dissociation rates are halved for both WT and H95A mutant (Fig. 2) . One explanation is that the mutation of H95 to Ala decreased the competitive binding potency but not the allosteric binding potency of DU124183. Another possible reason is that the temperature dependence of the affinity of DU124183 in WT (measured at 25°C) and H95A mutant receptors (measured at 4°C) may be different.
As we discussed in relation to the role of the highly conserved W243
6.48 in activation of the A 3 AR (Gao et al., 2002a,c) , the indole side chain displayed a characteristic movement in the model exclusively upon docking of agonist, whereas the unaltered geometry of the inactive conformation in the A 3 AR could accommodate the binding of antagonist. Consistent with N274 7.45 being constrained by the indole side chain of W243 6.48 in the inactive conformation and W243 6.48 participating in the hydrophobic interaction with the antagonist MRS1220 but not with the agonist Cl-IB-MECA, the N274A 7.45 mutation caused a dramatic affinity decrease for the antagonist MRS1220 but had little effect on binding of the agonist Cl-IB-MECA. Thus, mutation of those residues predicted in modeling to take part in the stabilizing the inactive conformation may also affect the binding of ligand indirectly.
Molecular modeling and experimental results suggested that multiple binding modes of the allosteric modulators may be possible, considering their small size and low affinity compared with orthosteric ligands. Multiple binding/modulatory sites have already been proposed to be present in some other GPCRs. There seem to be two distinct allosteric sites on the M 1 receptor (Birdsall et al., 2001) , and more than one allosteric site exists on the ␣ 1 -adrenergic receptor (Leppik and Birdsall, 2000) . Some agonists (e.g., demox) also suggested the possibility of interaction with both orthosteric and allosteric sites of the M 2 muscarinic receptor (Angeli et al., 2002) .
The possible location of the allosteric sites has been previously probed in several other GPCRs, although to a limited extent. In A 1 ARs, a T277A 7.42 mutation both diminished agonist affinity and inhibited the effect of the A 1 receptor enhancer PD81,723 (Kourounakis et al., 2001) . Distinct allosteric sites on the D 4 dopamine receptors have also been demonstrated by the study of sodium and zinc ions and methylisobutylamiloride (Schetz and Sibley, 2001) . A single amino acid in TM7 has been found to be critical to the muscarinic receptor subtype selectivities of caracurine V de- Table 1 are from three independent experiments in duplicate. Fig. 6 . Rhodopsin-based molecular model of the A 3 AR, showing the previously defined docking mode of the A 3 -selective agonist Cl-IB-MECA (colored according to atom type) and a putative allosteric binding site for VUF5455 (orange) on TM 7. Shown are selected residues near the allosteric modulator and residues F182 and N274, which were found to be important for the allosteric action of VUF5455. The secondary structure of each TM is displayed by ribbon using different colors, which indicate TMs 1, 2, 3, 4, 5, 6 , and 7 with red, orange, yellow, green, cyan, blue, and purple color, respectively. The coordinates of this A 3 AR model are available as from the Protein Data Bank ftp site under the name pdblo74.ent.Z. See http://www.rcsb.org/ pdb/pdb_news2002.html#models_removal2 for more information.
rivatives and alkane-bisammonium ligands (Buller et al., 2002) . In the M 1 muscarinic receptor, two residues, W101 and W400, are important for gallamine binding to the receptor, both in the unoccupied and in the antagonist (N-methylscopolamine)-bound state (Matsui et al., 1995) . The latter residue may have a structural role, because it was important for the binding of ACh and number of antagonists. Studies of residues responsible for the m2 receptor selectivity of gallamine have used both chimeric and point-mutated receptors. Residues have been found in EL2 and EL3, especially the "EDGE" sequence in EL2 of M 2 muscarinic receptors (in M 1 , the corresponding sequence is LAGQ) (Leppik et al., 1994; Gnagey et al., 1999) . It has been suggested that the gallamine binding site in the M 1 muscarinic receptor is located in the region of the receptor structure close to W400 and the LAGQ sequence, and the cleft represents the access route to the binding site of ACh and other polar agonists and antagonists (Birdsall et al., 2001) .
Through the study of muscarinic allosteric modulators, it was suggested that the allosteric site comprises the extracellular contact points located above the orthosteric site (Christopoulos et al., 1998) , which is itself postulated to be located in the upper third of the inner transmembrane pore (Wess, 1993 ). An allosteric binding site for various charged molecules may be near the orthosteric site of the muscarinic receptor but at a more extracellular level (Christopoulos and Kenakin, 2002) . Thus, a relatively vacant region at the top of TM6 and TM7 of the A 3 adenosine receptor was searched for the possibility location of an allosteric binding site. An energetically stabilized mode of docking of VUF5455 to the A 3 AR/ Cl-IB-MECA complex at this region of TM7 was identified (Fig. 6) .
Sodium ion binding to GPCRs is considered another form of allosteric modulation (negative) of the binding of agonists. The Asp 2.50 residue in TM2, which is conserved among GPCRs, is not generally important for ligand binding in the human A 3 AR; however, it is critical in sodium modulation at this and many other GPCRs. NaCl (100 mM) caused an ϳ80% inhibition of agonist binding in the WT A 3 The corresponding Asp 2.50 residue has been intensively studied in other GPCRs (Beukers et al., 1999) . It has been demonstrated that this Asp residue is critically involved in sodium modulation in ␣ 2 -adrenergic receptors (Horstman et al., 1990) , D 2 and D 4 dopamine receptors (Neve et al., 2001; Schetz and Sibley, 2001) , the A 1 AR (Barbhaiya et al., 1996) , and neurotensin receptors (Martin et al., 1999 7.46 at each vertex of the base and Asn423 7.49 at the apex (Teeter et al., 1994) . N52A
1.50 , N52L 1.50 , and S121L 3.39 mutations profoundly altered the properties in the mutant receptors, which exhibited no detectable binding of radioligands, and S121A 3.19 , S121N 3.39 , S420A 3.46 , and S420N 3.46 showed little or no dependence on sodium. With respect to the highly conserved (D/E)R(Y/W) motif in GPCRs, E134 3.49 in rhodopsin formed a salt-bridge with the guanidinium group of the adjacent R135 3.50 (Palczewski et al., 2000) . The calculated A 3 AR was stabilized by a number of interhelical H-bonds in a similar fashion: D107 3.49 H-bonded with T46  IL1 ,  T122 IL2 , R108 3.50 , and R111 IL2 (Fig. 7B) . Thus, mutation of residues that are important for the intramolecular TM network may affect the stability of the inactive conformation and consequently pharmacological properties of the A 3 AR. In the sodium experiment, the Ala mutant receptors of D58 2.50 , D107 3.49 , and F182 5.43 eliminated the modulation by sodium ions. It was suggested D58
2.50 and D107 3.49 might act as counter ions in direct sodium binding; however, F182 5.43 , which is separated from the putative sodium binding pocket, might play an indirect role in stabilizing an activated conformational state or in cooperativity, interacting with the lipid membrane or in aromatic-aromatic interaction.
In the inactive conformation of the A 3 AR, three amino acids, D58 
